Merck (MRK) EBITDA Margin (2009 - 2026)
Merck (MRK) posted quarterly EBITDA Margin of 47.46% for Q1 2026, down 6345.0% year-over-year from 0.76% in Q1 2025, and down 265.23% quarter-over-quarter from 12.99% in Q4 2025.
Merck (MRK) EBITDA Margin (2009 - 2026) Analysis & Trends
Merck (MRK) has reported EBITDA Margin for 18 consecutive years, with 47.46% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBITDA Margin fell 6345.0% year-over-year to 47.46%; the TTM figure through Mar 2026 stood at 8.41% (down 1638.0% YoY), while the FY2025 annual figure was 7.21%, down 19.0% from the prior year.
- EBITDA Margin eased to 47.46% in Q1 2026 per MRK's latest filing, from 12.99% in the prior quarter.
- Across five years, EBITDA Margin topped out at 16.73% in Q3 2025 and bottomed at 62.25% in Q2 2023.
- Historically, EBITDA Margin has averaged 5.39% across 5 years, with a median of 0.06% in 2024.
- Annual changes were most pronounced in 2023 — EBITDA Margin plunged 6411 bps — and 2024, when it surged 7628 bps.
- Merck's EBITDA Margin stood at 2.66% in 2022, then sank by 1430 bps to 40.72% in 2023, then jumped by 105 bps to 2.19% in 2024, then sank by 694 bps to 12.99% in 2025, then slumped by 265 bps to 47.46% in 2026.
- Business Quant data shows MRK's EBITDA Margin at 47.46% in Q1 2026, 12.99% in Q4 2025, and 16.73% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 28.21% |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 37.86% |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | -3.52% |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 32.97% |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 20.57% |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 34.95% |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | -133.21% |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 28.37% |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 5.72% |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 124.39% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -30.58% |
| Mar 31, 2026 | -47.46% |
| Dec 31, 2025 | -12.99% |
| Sep 30, 2025 | 16.73% |
| Jun 30, 2025 | 9.12% |
| Mar 31, 2025 | 16.00% |
| Dec 31, 2024 | 2.19% |
| Sep 30, 2024 | 0.06% |
| Jun 30, 2024 | 14.03% |
| Mar 31, 2024 | 13.50% |
| Dec 31, 2023 | -40.72% |
| Sep 30, 2023 | 8.50% |
| Jun 30, 2023 | -62.25% |
| Mar 31, 2023 | -1.91% |
| Dec 31, 2022 | -2.66% |
| Sep 30, 2022 | -2.35% |
| Jun 30, 2022 | 1.86% |
| Mar 31, 2022 | -3.26% |
| Dec 31, 2021 | 0.26% |
| Sep 30, 2021 | 13.81% |